| [1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
| [2] |
Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation[J]. N Engl J Med, 2002, 347(8): 567-575.
|
| [3] |
Cho HS, Mason K, Ramyar X, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J]．Nature, 2003, 421(6924): 756.
|
| [4] |
Del Mastro L, Lambertini M, Bighin C, et al. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients [J]. Expert Rev Anticancer Ther, 2012, 12(11): 1391-1405.
|
| [5] |
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of Trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group [J]．J Clin Oncol, 2005, 23(19): 4265-4274.
|
| [6] |
de Azambuja E, Bedard PL, Suter T, et al. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far？[J]．Target Oncol, 2009, 4(2): 77-88.
|
| [7] |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J]．N Engl J Med, 2011, 365(14): 1273-1283.
|
| [8] |
Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development [J]．Nature, 1995, 378(6555): 394-398.
|
| [9] |
Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes [J]. Biol Chem, 1998, 273(17): 10 261-10 269.
|
| [10] |
Pondé NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity[J]. ESMO Open, 2016, 1(4): e000073.
|
| [11] |
Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol, 2012, 30(31): 3792-3799.
|
| [12] |
de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01) [J]．J Clin Oncol, 2014, 32(20): 2159-2165.
|
| [13] |
Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer [J]. Clin Oncol, 2007, 25(25): 3808-3815.
|
| [14] |
Du XL, Xia R, Burau K, et al. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998－2005[J]. Med Oncol, 2011, 28 Suppl 1: S80-90.
|
| [15] |
Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with corrected human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. Clin Cancer Res, 2008, 14(19): 2710-2716.
|
| [16] |
Baselga J, Cortes J, Fumoleau P, et al. Pertuzumab and trastuzumab: Re-responses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately: A new biological and clinical observation [J]. Cancer Res, 2009, 69 (24 Suppl): 5114.
|
| [17] |
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2012, 13(1): 25-32.
|
| [18] |
Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase Ⅱ study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy [J]. J Clin Oncol, 2011, 29(4): 398-405.
|
| [19] |
Krop IE, Suter TM, Dang CT, et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer [J]. J Clin Oncol, 2015, 33(10): 1136-1142.
|
| [20] |
Tryfonidis K, Basaran G, Bogaerts J, et al. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase Ⅱ trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378) [J]．Eur J Cancer, 2016, 53: 144-154.
|
| [21] |
Carlson RW, O'Neill A, Vidaurre T, et al. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer [J]. Breast Cancer Res Treat, 2012, 133(3): 1049-1056.
|
| [22] |
Cristofanilli M, Valero V, Mangalik A, et al. Phase Ⅱ, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer [J]. Clin Cancer Res, 2010, 16(6): 1904-1914.
|
| [23] |
Osborne CK, Neven P, Dirix LY, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase Ⅱ study [J]. Clin Cancer Res, 2011, 17(5): 1147-1159.
|
| [24] |
Dickler MN, Cobleigh MA, Miller KD, et al. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer [J]. Breast Cancer Res Treat, 2009, 115(1): 115-121.
|
| [25] |
Kristensen TB, Knutsson ML, Wehland M, et al. Anti-vascular endothelial growth factor therapy in breast cancer [J]. Int J Mol Sci, 2014, 15(12): 23 024-23 041.
|
| [26] |
Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab [J]. J Clin Oncol, 2011, 29(6): 632-638.
|
| [27] |
Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and breast cancer: a meta-analysis of first-line phase Ⅲ studies and a critical reappraisal of available evidence[J]. J Oncol, 2012, 2012: 417 673.
|
| [28] |
Zhao M, Pan X, Layman R, et al. A phase Ⅱ study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer [J]. Invest New Drugs, 2014, 32(6): 1285-1294.
|
| [29] |
Miller KD, O'Neill A, Perez EA, et al. A phase Ⅱ pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophos-phamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group [J]．Ann Oncol, 2012, 23(2): 331-337.
|
| [30] |
Schneider BP, Li L, Shen F, et al. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100 [J]. Br J Cancer, 2014, 111(6): 1241-1248.
|
| [31] |
FDA Center for Drug Evaluation and Research. Memorandum to the file: BLA 125085 avastin (bevacizumab). Regulatory decision to withdraw avastin (bevacizumab) firstline metastatic breast cancer indication december 15, 2010.Accessed Sept.1, 2011[EB/OL]. [2016-07-01]．
URL
|
| [32] |
Richards CJ, Je Y, Schutz FA, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib[J]. J Clin Oncol, 2011, 29(25): 3450-3456.
|
| [33] |
Gradishar W, Kaklamani V, Sahoo TP, et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC) [J]. Cancer Res, 2009, 69(24 Suppl): 44.
|
| [34] |
Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials[J]. Mayo Clin Proc, 2008, 83(6): 679-686.
|
| [35] |
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J]. N Engl J Med, 2006, 355(26): 2733-2743.
|
| [36] |
Capri G, Chang J, Chen SC, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer [J]. Ann Oncol, 2010, 21(3): 474-480.
|
| [37] |
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet, 2012, 379(9816): 633-640.
|
| [38] |
Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial [J]. Lancet Oncol, 2012, 13(2): 135-144.
|
| [39] |
Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer [J]. J Clin Oncol, 2010, 28(8): 1301-1307.
|
| [40] |
Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2016, 17(3)；367-377.
|
| [41] |
Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial [J]. Lancet Oncol, 2011, 12(3): 236-244.
|
| [42] |
Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen [J]. Clin Cancer Res, 2007, 13(1): 228-233.
|
| [43] |
朱方清，杜凤彩，陈剑. 曲妥珠单抗在HER2阳性乳腺癌治疗中的心脏毒性及防治[J]. 癌症进展，2016，14(1)：40-42.
|
| [44] |
National Comprehensive Cancer Network(NCCN). NCCN clinical practice guidelines in oncology: breast cancer(version 1.2018)[EB/OL]．[2018-03-26].
URL
|
| [45] |
江泽飞，许凤锐. 2016乳腺癌精准医学发展：困境与出路[J/CD]．中华乳腺病杂志(电子版)，2017，11(2)：65-68.
|